Cytokinetics Targets Over 50% New-to-Brand Share for MYQORZO Amid U.K. Expansion
Cytokinetics (CYTK) reported strong execution during its Q3 period, driven primarily by the successful commercial launch of its cardiology drug, MYQORZO. CEO Robert I. Blum noted that the product's performance has exceeded initial company expectations. The company is aggressively pursuing market share, setting a goal to achieve more than 50% new-to-brand share by the end of the year. To fuel further growth, Cytokinetics plans to expand MYQORZO into the United Kingdom market within the current quarter.
Tickers: $CYTK
Topics: cardiology earnings call product launch revenue performance